Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.80 |
| ▸ | APP | P05067 | 1/20 | 0.66 |
| ▸ | CNR1 | P21554 | 8/20 | 0.57 |
| ▸ | CNR2 | P34972 | 8/20 | 0.57 |
| ▸ | BCHE | P06276 | 10/20 | 0.54 |
| ▸ | ACHE | P22303 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5421779 | 1.00 | SLC2A1 (0.80) | SLC2A1APPCNR1CNR2BCHE | |
| SCHEMBL30403756 | 1.00 | SLC2A1 (0.80) | SLC2A1APPCNR1CNR2BCHE | |
| SCHEMBL5411023 | 0.95 | SLC2A1 (0.73) | SLC2A1APPCNR1CNR2BCHE | |
| SCHEMBL14580341 | 0.95 | SLC2A1 (0.73) | SLC2A1APPCNR1CNR2BCHE | |
| SCHEMBL11671654 | 0.94 | SLC2A1 (0.91) | SLC2A1APPCNR1CNR2BCHE | |
| SCHEMBL908234 | 0.93 | SLC2A1 (0.69) | SLC2A1APPCNR1CNR2BCHE | |
| SCHEMBL5420745 | 0.93 | SLC2A1 (0.80) | SLC2A1APPCNR1CNR2BCHE | |
| SCHEMBL5408050 | 0.93 | SLC2A1 (0.80) | SLC2A1APPCNR1CNR2BCHE | |
| SCHEMBL11671890 | 0.92 | SLC2A1 (0.78) | SLC2A1APPCNR1CNR2BCHE | |
| SCHEMBL14580357 | 0.91 | SLC2A1 (0.75) | SLC2A1APPCNR1CNR2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116171276-A | 3- ((1H-pyrazol-4-yl) methyl) -6'- (phenyl) -2H- [1,2' -bipyridin ] -2-one derivatives and related compounds as GRP139 antagonists in methods of treating E.G. depression | 武田药品工业株式会社 | 2023-05-26 | — | — | CN | disclosed |
| US-9453000-B2 | Polycyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| EP-2559693-B1 | Polycyclic compound | EISAI R&D MAN CO LTD (JP) | 2014-11-26 | — | — | EP | disclosed |
| EP-2181992-B1 | POLYCYCLIC COMPOUND | EISAI R&D MAN CO LTD (JP) | 2013-05-01 | — | — | EP | disclosed |
| EP-2559693-A1 | Polycyclic compound | Eisai R&D Management Co., Ltd. (JP) | 2013-02-20 | — | — | EP | disclosed |
| US-7935815-B2 | Imidazoyl pyridine compounds and salts thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20110065696-A1 | IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF | KIMURA TEIJI | 2011-03-17 | — | — | US | disclosed |
| US-20110009619-A1 | POLYCYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2181992-A1 | POLYCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2010-05-05 | — | — | EP | disclosed |
| EP-2148673-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | Eisai R&D Management Co., Ltd. (JP) | 2010-02-03 | — | — | EP | disclosed |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2009-03-05 | — | — | US | disclosed |
| WO-2008139984-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-11-20 | — | — | WO | disclosed |
| US-7173061-B2 | Compounds for imaging alzheimer's disease | GE HEALTHCARE LIMITED (GB) | 2007-02-06 | — | — | US | disclosed |
| US-7173061-B2 | Compounds for imaging alzheimer's disease | GE HEALTHCARE LIMITED (GB) | 2007-02-06 | — | — | US | disclosed |
| US-7173061-B2 | Compounds for imaging alzheimer's disease | GE HEALTHCARE LIMITED (GB) | 2007-02-06 | — | — | US | disclosed |
| EP-1463721-B1 | COMPOUNDS FOR IMAGING ALZHEIMER'S DISEASE | GE HEALTHCARE LTD (GB) | 2005-11-23 | — | — | EP | disclosed |
| US-20050080130-A1 | Compounds foriImaging alzheimer's disease | GE HEALTHCARE LIMITED (GB) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | GRIN1, GRIN2A, GRIN3A | SLC2A1 2321/4885APP 34/4885CNR1 197/4885 |
| US-20110009619-A1 | POLYCYCLIC COMPOUND | APP, BACE1, PSEN1 | SLC2A1 3493/4885APP 1/4885CNR1 120/4885 |
| US-20050080130-A1 | Compounds foriImaging alzheimer's disease | PSEN1, APP, PSEN2 | SLC2A1 901/4885APP 2/4885CNR1 1138/4885 |
| US-20110065696-A1 | IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF | APP, PSEN1, BACE1 | SLC2A1 3690/4885APP 1/4885CNR1 184/4885 |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | APP, BACE1, PSEN1 | SLC2A1 4002/4885APP 1/4885CNR1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.